HIPRA, with over 50 years of experience in the development of biological products, presents HIPRA Biotech Services, its new division dedicated to providing development and manufacturing services for biological products to companies in the biotechnology and pharmaceutical sectors. As a contract development and manufacturing organization (CDMO), HIPRA Biotech Services covers the entire product lifecycle, from the initial phases of research and development to commercial-scale production. This comprehensive offering includes multiple technologies and biological modalities, providing clients with flexibility, customized solutions, and the highest quality, in compliance with international regulatory agency requirements.
“With HIPRA Biotech Services, we bring the knowledge and expertise accumulated over more than 50 years in biotechnology to other companies, along with our technical and scientific capabilities and our commitment to excellence. For decades, we have been a strategic leader in animal health, delivering innovative and high-quality solutions. In recent years, we have successfully extended our expertise to human health, enabling us to offer comprehensive knowledge in the development and manufacturing of biologicals. This CDMO model reflects our mission to provide innovative and sustainable solutions that contribute to improving global health,” said Carles Fàbrega, Managing Director of HIPRA Human Health.
State-of-the-art facilities: proximity and efficiency
HIPRA’s facilities are located in Spain, specifically in the province of Girona, with a nearby location that fosters excellent connectivity between all phases of the process, from development to the manufacturing of the final product. This location, at the heart of the European Union, reinforces HIPRA's commitment to European strategic autonomy, offering solutions that ensure the safety and sustainability of the supply chain. Its integrated “end-to-end” model facilitates agile decision-making and enables rapid progress in the development, scaling, and commercial manufacturing of biological active ingredients and finished sterile products.
Production capacity: from small projects to large-scale productions
The facilities are designed to handle both small projects and large-scale industrial productions, offering the flexibility required to adapt to market demands.
In summary, the new unit will make available over 7,000 Liters of bioreactor capacity for mammalian cell culture and more than 8,000 Liters of fermentation capacity for microbial cultures. Additionally, an aseptic vial filling line with isolator technology is in place. These capacities position HIPRA Biotech Services as one of Europe’s leading CDMOs for the manufacturing of biological products.
HIPRA Biotech Services has a multidisciplinary team of 1,400 highly qualified professionals from various fields such as scientists, engineers, operators, and analysts, among others. This team collaborates closely with clients to provide customized solutions that meet the market’s most demanding requirements, ensuring quality in all stages of the process.
“Our combination of advanced technology, cutting-edge infrastructure, and a team characterized by optimism in the face of challenges and a commitment to clients’ projects makes us a strategic and flexible partner. We are prepared to respond with technical excellence and operational agility to the challenges of an increasingly competitive market without compromising our internal production capacity”, explained Fàbrega.
The new unit is led by Eduard Viladesau, General Manager of HIPRA Biotech Services. Viladesau joins the team after an 18-year career at Boston Consulting Group, where he focused on Operations for the pharmaceutical industry and led the CDMO area. His incorporation is essential to driving this new unit, further strengthening HIPRA’s commitment to quality and excellence in the development and production of biological products.
Advanced infrastructure and commitment to sustainability
HIPRA’s production centers feature state-of-the-art technology for manufacturing biological active substances and sterile finished products, adhering to the highest international standards of quality and sustainability. The full automation of the production chain enhances efficiency and minimizes risks.
Additionally, the company maintains a strong commitment to reducing its environmental footprint by promoting responsible and efficient production processes. The optimal management of energy and water resources and the implementation of eco-efficient technologies enable the company to surpass its own environmental and operational standards year after year.
